This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly Begins Phase III Study on Olumiant for Coronavirus
by Zacks Equity Research
Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.
REGN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
Teladoc (TDOC) Soars 193% in a Year: What's Behind the Rally?
by Zacks Equity Research
Teladoc (TDOC) continues to benefit from constant top-line growth and strategic initiatives, which have been aiding its share price.
Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Regeneron Initiates Study on Antibody Cocktail for Coronavirus
by Zacks Equity Research
Regeneron (REGN) initiates study on its antibody cocktail, REGN-COV2, for the prevention and treatment of COVID-19.
Novartis' (NVS) Beovu Gets FDA Approval for Label Update
by Zacks Equity Research
Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.
Pfizer's Eczema Candidate Meets All Goals in Study on Teens
by Zacks Equity Research
Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.
Regeneron (REGN) Stock Moves -0.33%: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $606.59, marking a -0.33% move from the previous day.
Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
by Zacks Equity Research
Lilly (LLY) is set to study JS016 as a monotherapy and in combination with antibody treatments including LY-CoV555, its first potential COVID-19 antibody candidate that recently entered phase I.
AstraZeneca's Calquence Shows Promise as Coronavirus Treatment
by Zacks Equity Research
Peer-reviewed data on AstraZeneca's (AZN) Calquence shows that it improves laboratory markers of inflammation and decreases oxygen requirements in most patients hospitalized due to COVID-19.
Alnylam Reports Positive Phase III Results on Lumasarin
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
Novartis' Asthma Treatment Meets Primary Endpoint in Phase III
by Zacks Equity Research
Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.
Why Is Regeneron (REGN) Up 9.2% Since Last Earnings Report?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
Regeneron Expands Deal With Intellia for Hemophilia Treatments
by Zacks Equity Research
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
REGN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: T-Mobile US, Citigroup, Blackstone Group, Regeneron Pharmaceuticals and Canadian National Railway
by Zacks Equity Research
The Zacks Analyst Blog Highlights: T-Mobile US, Citigroup, Blackstone Group, Regeneron Pharmaceuticals and Canadian National Railway
Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 6.3%
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Can Regeneron (REGN) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
Top Research Reports for T-Mobile, Citigroup & Blackstone
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US (TMUS), Citigroup (C) and Blackstone Group (BX).
Sanofi's Dupixent Gets FDA Approval for Eczema in Children
by Zacks.com
Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.